Abstract
Antifibronectin autoantibodies (AFA) have been detected in the serum and synovial fluid of patients with systemic lupus erythematosus (SLE), rheumatoid arthritis, and systemic vasculitis; they predominantly recognize the native form of the antigen. In SLE, these antibodies are directed mainly against the 30-kDa collagen-binding domain of the fibronectin molecule, and they correlate with disease activity and musculoskeletal manifestations. However, since AFA are not specific for any particular autoimmune disease, their diagnostic value is low. In contrast, autoantibodies against citrullinated fibronectin were described to be specific for early and established rheumatoid arthritis. However, further studies are required to clarify whether these antibodies are involved in the pathogenesis of disease. Furthermore, standardized assays are required to investigate their value as diagnostic markers in rheumatoid arthritis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
